日本語フィールド
著者：○Sakiko Kimura, Kazuhisa Hosoya, Kenji Ogata, Tatsuya Furuno, Rintaro Sogawa, Koji Takeuchi, Masanobu Tasaki, Atsushi Kawaguchi, Atsujiro Nishioka, Naoko Sueoka-Aragane, Hirokazu Noshiro, Yuichiro Kuratomi, Masatoshi Yokoyama, Mitsuru Noguchi, Keizo Anzai, Yoshio Yamashita, Shinya Kimura, Hiroyuki Irie題名：Severity of constipation related to palonosetron during first-line chemotherapy: a retrospective observational study 発表情報：Support Care Cancer 巻: 29 号: 8 ページ: 4723-4732キーワード：Aprepitant; Cancer patients; Constipation; Palonosetron; The elderly概要：Purpose: Palonosetron, a long-acting 5-HT3 receptor antagonist, is an effective antiemetic agent for chemotherapy-induced nausea and vomiting; however, it sometimes causes severe constipation. The aim of the present study was to evaluate the severity of palonosetron-related constipation.
Methods: We retrospectively analyzed the incidence and severity of constipation after intravenous administration of 0.75-mg palonosetron in 150 chemotherapy-na?ve patients who received first-line chemotherapy at Saga University Hospital. Constipation was classified into grades 1-5 according to the Common Terminology Criteria for Adverse Events version 5.0. Multiple logistic regression analysis was performed to identify factors associated with palonosetron-related worsening of constipation to grade 2 or higher.
Results: Palonosetron significantly increased the incidence and severity of constipation (incidence: before vs. after palonosetron, 35.4% vs. 74.0%, p < 0.0001, and severity: before vs. after palonosetron, 26.7% and 8.7% in grades 1 and 2, respectively, vs. 46.7%, 23.3%, and 4.0% in grades 1, 2, and 3, respectively, p < 0.0001). Despite the use of laxatives, 4.0% of patients had grade 3 constipation requiring manual evacuation. Combination treatment with aprepitant (odds ratio (OR), 10.9; 95% confidence interval (CI), 1.3-90.0; p = 0.026) and older age (OR, 1.25; 95% CI, 1.01-1.57; p = 0.039) were factors associated with the severity of constipation.
Conclusion: Constipation was more severe in patients receiving combination treatment with aprepitant than in those treated with palonosetron alone. Older age was also associated with increased risk of severe palonosetron-related constipation. Identification of risk factors can help target risk-based laxative therapy.抄録：英語フィールド
Author：○Sakiko Kimura, Kazuhisa Hosoya, Kenji Ogata, Tatsuya Furuno, Rintaro Sogawa, Koji Takeuchi, Masanobu Tasaki, Atsushi Kawaguchi, Atsujiro Nishioka, Naoko Sueoka-Aragane, Hirokazu Noshiro, Yuichiro Kuratomi, Masatoshi Yokoyama, Mitsuru Noguchi, Keizo Anzai, Yoshio Yamashita, Shinya Kimura, Hiroyuki IrieTitle：Severity of constipation related to palonosetron during first-line chemotherapy: a retrospective observational study Announcement information:Support Care Cancer Vol: 29 Issue: 8 Page: 4723-4732Keyword：Aprepitant; Cancer patients; Constipation; Palonosetron; The elderlyAn abstract：Purpose: Palonosetron, a long-acting 5-HT3 receptor antagonist, is an effective antiemetic agent for chemotherapy-induced nausea and vomiting; however, it sometimes causes severe constipation. The aim of the present study was to evaluate the severity of palonosetron-related constipation.
Methods: We retrospectively analyzed the incidence and severity of constipation after intravenous administration of 0.75-mg palonosetron in 150 chemotherapy-na?ve patients who received first-line chemotherapy at Saga University Hospital. Constipation was classified into grades 1-5 according to the Common Terminology Criteria for Adverse Events version 5.0. Multiple logistic regression analysis was performed to identify factors associated with palonosetron-related worsening of constipation to grade 2 or higher.
Results: Palonosetron significantly increased the incidence and severity of constipation (incidence: before vs. after palonosetron, 35.4% vs. 74.0%, p < 0.0001, and severity: before vs. after palonosetron, 26.7% and 8.7% in grades 1 and 2, respectively, vs. 46.7%, 23.3%, and 4.0% in grades 1, 2, and 3, respectively, p < 0.0001). Despite the use of laxatives, 4.0% of patients had grade 3 constipation requiring manual evacuation. Combination treatment with aprepitant (odds ratio (OR), 10.9; 95% confidence interval (CI), 1.3-90.0; p = 0.026) and older age (OR, 1.25; 95% CI, 1.01-1.57; p = 0.039) were factors associated with the severity of constipation.
Conclusion: Constipation was more severe in patients receiving combination treatment with aprepitant than in those treated with palonosetron alone. Older age was also associated with increased risk of severe palonosetron-related constipation. Identification of risk factors can help target risk-based laxative therapy.